Insight

The promise of immuno-oncology in the neoadjuvant setting – ESMO

Photo taken from ESMO/LinkedIn

Jun 27, 2024, 09:10

The promise of immuno-oncology in the neoadjuvant setting – ESMO

The European Society for Medical Oncology (ESMO) shared on LinkedIn:

“The promise of immuno-oncology in the neoadjuvant setting.

Recent studies highlight novel pre-operative therapeutic options that are showing promise.

While there are still challenges to address, early clinical trials in the neoadjuvant setting could pave the way for practice-changing strategies to help a larger number of people with cancer.

To learn more about this topic, read the ESMO Daily Reporter new column by Elena Garralda Cabanas.”

Source: ESMO/LinkedIn

cancer clinical trials Elena Garralda Cabanas ESMO ESMO Daily Reporter immuno-oncology neoadjuvant setting OncoDaily Oncology The European Society for Medical Oncology

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage